Drug intelligence / Profile preview

pentoxifylline + sulfasalazine

Development stage: Unknown
Lead developer: Hoechst
Modality: Small Molecules
Administration: Oral

Overview

A combination of pentoxifylline and sulfasalazine used as adjuvant therapy in autoimmune conditions, particularly pemphigus vulgaris. Both drugs work synergistically to reduce tumor necrosis factor alpha (TNF-α) levels through independent mechanisms. Pentoxifylline reduces TNF-α production by inhibiting phosphodiesterase, while sulfasalazine inhibits TNF-α messenger RNA levels and binds to circulating TNF-α. This low-cost combination offers an alternative to more expensive biologic TNF-α inhibitors and traditional immunosuppressants with fewer side effects.

Targets

PLA2 (Phospholipase A2 group IID)PGHS-1 (Prostaglandin G/H Synthase 1)PDE (Phosphodiesterase family)

Beyond the preview

Go deeper on pentoxifylline + sulfasalazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pentoxifylline + sulfasalazine.

Explore the full profile